Iwai T, Nakamura H, Takanashi H, Yogo K, Ozaki K, Ishizuka N, Asano T
Chugai Pharmaceutical Co. Ltd., Fuji-Gotemba Research Labs, Shizuoka, Japan.
Can J Physiol Pharmacol. 1998 Dec;76(12):1103-9. doi: 10.1139/cjpp-76-12-1103.
The effects of [Leu13]motilin were examined in vivo after its intravenous administration into anesthetized dogs and in vitro with isolated preparations of canine mesenteric artery. [Leu13]Motilin (0.1-10 nmol x kg(-1), i.v.) induced both strong and clustered phasic contractions in the gastric antrum and duodenum. At doses of over 1 nmol x kg(-1), [Leu13]motilin also produced transient decreases in arterial blood pressure, left ventricular pressure, maximum rate of rise of left ventricular pressure, and total peripheral resistance, and an increase in aortic blood flow and heart rate. A selective motilin antagonist, GM-109 (Phe-cyclo[Lys-Tyr(3-tBu)-betaAla] trifluoroacetate), completely abolished the gastric antrum and duodenal motor responses induced by [Leu13]motilin. In contrast, hypotension induced by [Leu13]motilin (1 nmol x kg(-1)) was unchanged in the presence of GM-109. In isolated mesenteric artery preparations precontracted with U-46619 (10(-7) M), [Leu13]motilin (10(-8)-10(-5) M) induced an endothelium-dependent relaxation, and this was inhibited by a pretreatment with N(omega)-nitro-L-arginine, a competitive inhibitor of NO synthase (10(-4) M). A high dose (10(-4) M) of GM-109 slightly decreased [Leu13]motilin-induced relaxation, and shifted the concentration-response curve of [Leu13]motilin to the right. However, the pA2 value (4.09) of GM-109 for [Leu13]motilin in the present study was conspicuously lower than that previously demonstrated in the rabbit duodenum (7.37). These results suggest that [Leu13]motilin induces hypotension via the endothelial NO-dependent relaxation mechanism and not through the receptor type that causes upper gastrointestinal contractions.
在麻醉犬体内静脉注射[亮氨酸13]胃动素后,以及在体外用犬肠系膜动脉分离标本进行实验,研究了[亮氨酸13]胃动素的作用。静脉注射[亮氨酸13]胃动素(0.1 - 10 nmol·kg⁻¹)可引起胃窦和十二指肠强烈且成簇的相性收缩。剂量超过1 nmol·kg⁻¹时,[亮氨酸13]胃动素还会使动脉血压、左心室压力、左心室压力最大上升速率和总外周阻力短暂下降,同时使主动脉血流量和心率增加。一种选择性胃动素拮抗剂GM - 109(苯丙氨酸 - 环[赖氨酸 - 酪氨酸(3 - 叔丁基) - β丙氨酸]三氟乙酸盐)可完全消除[亮氨酸13]胃动素诱导的胃窦和十二指肠运动反应。相比之下,在GM - 109存在的情况下,[亮氨酸13]胃动素(1 nmol·kg⁻¹)诱导的低血压没有变化。在预先用U - 46619(10⁻⁷ M)预收缩的离体肠系膜动脉标本中,[亮氨酸13]胃动素(10⁻⁸ - 10⁻⁵ M)可诱导内皮依赖性舒张,而这种舒张可被一氧化氮合酶竞争性抑制剂N(ω) - 硝基 - L - 精氨酸(10⁻⁴ M)预处理所抑制。高剂量(10⁻⁴ M)的GM - 109可轻微降低[亮氨酸13]胃动素诱导的舒张,并使[亮氨酸13]胃动素的浓度 - 反应曲线右移。然而,本研究中GM - 109对[亮氨酸13]胃动素的pA2值(4.09)明显低于先前在兔十二指肠中所显示的值(7.37)。这些结果表明,[亮氨酸13]胃动素通过内皮一氧化氮依赖性舒张机制诱导低血压,而非通过引起上消化道收缩的受体类型。